Literature DB >> 30610523

18F-FDG uptake of the right ventricle is an important predictor of histopathologic diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis.

Kazunori Omote1, Masanao Naya2, Kazuhiro Koyanagawa1, Tadao Aikawa1, Osamu Manabe3, Toshiyuki Nagai1, Kiwamu Kamiya1, Yoshiya Kato1, Hirokazu Komoriyama1, Masato Kuzume1, Nagara Tamaki4, Toshihisa Anzai1.   

Abstract

BACKGROUND: The aim of this study was to determine whether right ventricle (RV) 18F-fluorodeoxyglucose (FDG) uptake can predict positive findings of endomyocardial biopsy (EMB) in patients with cardiac sarcoidosis (CS).
METHODS: 70 consecutive patients with clinically diagnosed CS who had undergone FDG PET were registered in the present study. Patients without EMB (n = 42) were excluded. Ultimately, 28 patients were studied. EMB samples were obtained from the RV septum. We evaluated the FDG uptake on six segments (RV, left ventricle anterior, septal, lateral, inferior, and apex).
RESULTS: Positive EMB was found in six patients (21%). Patients were divided into two groups according to positive (n = 12 [43%]) or negative (n = 16 [57%]) RV FDG uptake. Patients with positive RV FDG uptake had a significantly higher frequency of positive EMB than those without (42% vs. 6%, P = 0.024). On the other hand, there was no EMB-predictive value for the FDG uptakes in the other five segments, the cardiac metabolic volume, total lesion glycolysis, left ventricular ejection fraction, or any electrocardiogram findings.
CONCLUSIONS: FDG uptake of the RV but no other heart segment was associated with positive EMB in CS patients. The presence of RV FDG uptake could improve the rate of positive EMB up to 42% in patients with CS.

Entities:  

Keywords:  18F-fluorodeoxyglucose positron emission tomography; Cardiac sarcoidosis; endomyocardial biopsy; right ventricle

Mesh:

Substances:

Year:  2019        PMID: 30610523     DOI: 10.1007/s12350-018-01541-7

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  5 in total

1.  Imaging cardiac sarcoidosis with FDG-PET: Take a look at the right side!

Authors:  Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2019-02-15       Impact factor: 5.952

2.  Prognostic insights of molecular imaging in cardiac sarcoidosis.

Authors:  Riccardo Laudicella; Fabio Minutoli; Sergio Baldari
Journal:  J Nucl Cardiol       Date:  2019-04-03       Impact factor: 5.952

3.  Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.

Authors:  Pratik S Velangi; Ko-Hsuan Amy Chen; Felipe Kazmirczak; Osama Okasha; Lisa von Wald; Henri Roukoz; Afshin Farzaneh-Far; Jeremy Markowitz; Prabhjot S Nijjar; Maneesh Bhargava; David Perlman; Mehmet Akçakaya; Chetan Shenoy
Journal:  JACC Cardiovasc Imaging       Date:  2020-01-15

Review 4.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

Review 5.  Advances in Diagnostic Imaging for Cardiac Sarcoidosis.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Tadao Aikawa; Satonori Tsuneta; Nagara Tamaki
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.